文献速递浆细胞疾病

巨细胞病毒血清阳性与多发性骨髓瘤患者对CD38单克隆抗体治疗应答改善相关:单中心回顾性研究

Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single-centre retrospective study.
PubMed 文献 · Br J Haematol · 2023-02-27

该单中心回顾性研究纳入136例已知巨细胞病毒(CMV)血清状态、接受含CD38单克隆抗体方案的多发性骨髓瘤患者,其中93.4%使用达雷妥尤单抗、6.6%使用伊沙妥昔单抗。CMV血清阳性与含CD38单克隆抗体方案总缓解率升高相关(比值比2.65,95%CI 1.17-6.02),但在多变量Cox模型中与更短的治疗失败时间相关(CMV血清阳性组7.8个月 vs 血清阴性组8.8个月,log-rank P=0.18,风险比1.98,95%CI 1.25-3.12)。作者认为CMV血清阳性可能预测对CD38单克隆抗体更好的应答,但这并未对应更长的治疗失败时间,需更大规模直接定量g-NK细胞的研究来充分理解其影响。

要点

  • CMV血清阳性与含CD38单克隆抗体方案总缓解率升高相关(OR 2.65,95%CI 1.17-6.02)。
  • 多变量Cox模型中CMV血清阳性与更短治疗失败时间相关(7.8 vs 8.8个月,HR 1.98,95%CI 1.25-3.12)。
  • 作者认为CMV血清阳性可能预测更好应答,但未对应更长治疗失败时间,需更大研究直接定量g-NK细胞。

核心结论

  • 数据提示CMV血清阳性可能预测对CD38单克隆抗体更好的应答,但这并未对应更长的治疗失败时间。
  • 需更大规模直接定量g-NK细胞的研究来充分理解其对多发性骨髓瘤中CD38单克隆抗体疗效的影响。

研究设计与样本

  • 单中心、回顾性分析,纳入136例已知CMV血清状态、接受含CD38单克隆抗体方案的多发性骨髓瘤患者。
  • 治疗方案中93.4%为达雷妥尤单抗,6.6%为伊沙妥昔单抗。

主要发现

  • CMV血清阳性与含CD38单克隆抗体方案总缓解率升高相关(比值比2.65,95%CI 1.17-6.02)。
  • 多变量Cox模型中CMV血清状态与更短的治疗失败时间相关:CMV血清阳性组7.8个月 vs CMV血清阴性组8.8个月(log-rank P=0.18,风险比1.98,95%CI 1.25-3.12)。

局限性

  • 作者指出需更大规模直接定量g-NK细胞的研究来充分理解其对CD38单克隆抗体疗效的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The CD38-targeting monoclonal antibodies (CD38 mAbs) are well-established therapies in multiple myeloma (MM), but responses to treatment are not always deep or durable. Natural killer (NK) cells deficient in Fc epsilon receptor gamma subunits, known as g-NK cells, are found in higher numbers among individuals exposed to cytomegalovirus (CMV) and are able to potentiate the efficacy of daratumumab in vivo. Here, we present a single-centre, retrospective analysis of 136 patients with MM with known CMV serostatus who received a regimen containing a CD38 mAb (93.4% daratumumab and 6.6% isatuximab). CMV seropositivity was associated with an increased overall response rate to treatment regimens containing a CD38 mAb (odds ratio 2.65, 95% confidence interval [CI] 1.17-6.02). However, CMV serostatus was associated with shorter time to treatment failure in a multivariate Cox model (7.8 vs. 8.8 months in the CMV-seropositive vs. CMV-seronegative groups respectively, log-rank p = 0.18, hazard ratio 1.98, 95% CI 1.25-3.12). Our data suggest that CMV seropositivity may predict better response to CD38 mAbs, although this did not correspond to longer time to treatment failure. Larger studies directly quantitating g-NK cells are required to fully understand their effect on CD38 mAb efficacy in MM.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ge AY, Huang CY, Banerjee R, et al. Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single-centre retrospective study. Br J Haematol. 2023. PMID: 36846905. doi:10.1111/bjh.18711

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。